Switzerland· 61297002
VPRIV 400 U, Pulver zur Herstellung einer Infusionslösung
A velaglucerase alfa product containing velaglucerasum alfa, registered in Switzerland by Takeda Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Velaglucerase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB10 (velaglucerase alfa), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Velaglucerase alfa · ATC A16AB10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- velaglucerasum alfa
- Manufacturer
- Takeda Pharma AG
- Country
- Switzerland (CH)
- ATC code
- A16AB10
- ATC class
- Velaglucerase alfa
- Defined daily dose
- 300 E, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680612970026Durchstf 1 StkCHF 2145.65
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Velaglucerase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVprivShire Pharmaceuticals Ireland Ltd.
- CzechiaVPRIVTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- SwedenVPRIV 200 E Pulver till infusionsvätska, lösningShire Pharmaceuticals Ireland Limited
- BelgiumVpriv 200 IUShire Pharmaceuticals Ireland
- United KingdomVPRIV 400units powder for solution for infusion vialsTakeda UK Ltd
- IrelandVPRIV 400 Units powder for solution for infusionShire Pharmaceuticals Ireland Limited
- IcelandVPRIVTakeda Pharmaceuticals International AG Ireland Branch
- Japanベラグルセラーゼ アルファ（遺伝子組換え）武田薬品工業
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vpriv
- Liechtenstein · Vpriv
- Norway · Vpriv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d1f47cc1-a19d-439e-8f19-7ce2809b28c2 GET /v1/drugs/d1f47cc1-a19d-439e-8f19-7ce2809b28c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "velaglucerasum alfa 400 U",
"valid_from": "2010-11-01",
"limitations": "[{\"description\":\"Zur Langzeit-Enzymersatztherapie bei Patienten mit Gaucher-Krankheit des Typ1.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2010-11-01\"}]",
"galenic_form": "Trockensub 400 IE",
"therapeutic_area": null,
"sl_inclusion_date": "2010-11-01",
"self_retention_pct": 10
}See everything about velaglucerase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.